76 related articles for article (PubMed ID: 16651854)
21. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer.
Lesniak D; Xu Y; Deschenes J; Lai R; Thoms J; Murray D; Gosh S; Mackey JR; Sabri S; Abdulkarim B
Cancer Res; 2009 Nov; 69(22):8620-8. PubMed ID: 19887601
[TBL] [Abstract][Full Text] [Related]
22. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
[TBL] [Abstract][Full Text] [Related]
23. The activation of an extracellular signal-regulated kinase by oestradiol interferes with the effects of trastuzumab on HER2 signalling in endometrial adenocarcinoma cell lines.
Treeck O; Diedrich K; Ortmann O
Eur J Cancer; 2003 Jun; 39(9):1302-9. PubMed ID: 12763221
[TBL] [Abstract][Full Text] [Related]
24. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
Junttila TT; Akita RW; Parsons K; Fields C; Lewis Phillips GD; Friedman LS; Sampath D; Sliwkowski MX
Cancer Cell; 2009 May; 15(5):429-40. PubMed ID: 19411071
[TBL] [Abstract][Full Text] [Related]
25. Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells.
Tatebe H; Shimizu M; Shirakami Y; Tsurumi H; Moriwaki H
Clin Cancer Res; 2008 May; 14(9):2806-12. PubMed ID: 18451248
[TBL] [Abstract][Full Text] [Related]
26. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
[TBL] [Abstract][Full Text] [Related]
27. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
[TBL] [Abstract][Full Text] [Related]
28. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
29. An overview of HER2.
Lohrisch C; Piccart M
Semin Oncol; 2001 Dec; 28(6 Suppl 18):3-11. PubMed ID: 11774200
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.
Marches R; Uhr JW
Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077
[TBL] [Abstract][Full Text] [Related]
31. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling.
Mullen P; Cameron DA; Hasmann M; Smyth JF; Langdon SP
Mol Cancer Ther; 2007 Jan; 6(1):93-100. PubMed ID: 17237269
[TBL] [Abstract][Full Text] [Related]
32. Human Serum Albumin and HER2-Binding Affibody Fusion Proteins for Targeted Delivery of Fatty Acid-Modified Molecules and Therapy.
Dong D; Xia G; Li Z; Li Z
Mol Pharm; 2016 Oct; 13(10):3370-3380. PubMed ID: 27546214
[TBL] [Abstract][Full Text] [Related]
33. The novel dithiocarbamate, DpdtC suppresses HER2-overexpressed cancer cells by up-regulating NDRG1 via inactivation of HER2-ERK 1/2 signaling.
Yang Y; Liu Y; Guo R; Fu Y; Zhang Z; Zhang P; Zhou P; Wang T; Huang T; Li X; Li C
Sci Rep; 2018 Feb; 8(1):3398. PubMed ID: 29467385
[TBL] [Abstract][Full Text] [Related]
34. Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts.
Oroujeni M; Tano H; Vorobyeva A; Liu Y; Vorontsova O; Xu T; Westerlund K; Orlova A; Tolmachev V; Karlström AE
J Nucl Med; 2022 Jul; 63(7):1046-1051. PubMed ID: 34711617
[TBL] [Abstract][Full Text] [Related]
35. Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells.
Damiani I; Castiglioni S; Sochaj-Gregorczyk A; Bonacina F; Colombo I; Rusconi V; Otlewski J; Corsini A; Bellosta S
Biology (Basel); 2021 Aug; 10(8):. PubMed ID: 34439990
[TBL] [Abstract][Full Text] [Related]
36. A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines.
Sochaj-Gregorczyk AM; Serwotka-Suszczak AM; Otlewski J
J Immunother; 2016; 39(6):223-32. PubMed ID: 27227324
[TBL] [Abstract][Full Text] [Related]
37. Imaging of HER-2 overexpression in tumors for guiding therapy.
Tolmachev V
Curr Pharm Des; 2008; 14(28):2999-3019. PubMed ID: 18991715
[TBL] [Abstract][Full Text] [Related]
38. Structural basis for high-affinity HER2 receptor binding by an engineered protein.
Eigenbrot C; Ultsch M; Dubnovitsky A; Abrahmsén L; Härd T
Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15039-44. PubMed ID: 20696930
[TBL] [Abstract][Full Text] [Related]
39. Bispecific Antibody Molecule Inhibits Tumor Cell Proliferation More Efficiently Than the Two-Molecule Combination.
Volk AL; Mebrahtu A; Ko BK; Lundqvist M; Karlander M; Lee HJ; Frejd FY; Kim KT; Lee JS; Rockberg J
Drugs R D; 2021 Jun; 21(2):157-168. PubMed ID: 33721246
[TBL] [Abstract][Full Text] [Related]
40. Improvement of Targeted Chemotherapy of HER2-positive Ovarian Malignant Cell Line by Z
Siavoshinia L; Jamalan M; Zeinali M; Pourshohod A; Koushki M; Moradipoodeh B; Mohammadzadeh G
Iran J Pathol; 2021; 16(2):109-118. PubMed ID: 33936221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
